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IC is the third to fourth most common cause of bloodstream infections in ICUs in the United States [2] . Th is infection is associated with substantial mortality (40%) and increased healthcare costs (approximately $40,000) [3] . Considerable research has been undertaken to identify patients at high risk for this infection and may benefi t from prophylaxis or early therapy strategies, such as pre-emptive therapy and empirical therapy [4, 5] .
Hermsen and colleagues have attempted to validate two clinical prediction rules for IC in ICU patients in the setting of a case control study using contemporary patients from the Nebraska Medical Center. During the study period, the overall incidence of IC in patients with a length of stay ≥4 days was 2.3%, which is the typical incidence of IC seen in most ICUs in the US. Hermsen and colleagues selected patients with invasive candidiasis and matched them to three uninfected controls to validate the performance of the Paphitou [6] and OstroskyZeichner rules [7] . Th ese two rules were originally constructed through retrospective chart reviews and logistic regression to identify high risk patients for a multicenter clinical trial of antifungal prophylaxis in the ICU setting. In their validation, Hermsen and colleagues found that the Paphitou rule had sensitivity approximately 40%, specifi city approximately 80%, and an unusually low positive predictive value (PPV) with a negative predictive value (NPV) >98%. Th e Ostrosky-Zeichner rule had sensitivity approximately 70%, specifi city approximately 60%, with similar PPV and NPV performance. Th ey then proceeded to create their own prediction rule (NMC rule), which includes any broad-spectrum anti biotic use, central venous catheter (D1 to D3), abdominal surgery (D-7 to D3), immunosuppressants (D-7 to D0), total parenteral nutrition (D1 to D3) and mean pre-ICU length of stay. Th e performance of their rule was reported as sensitivity 84.1%, specifi city 60.2%, PPV 4.7%, NPV 99.4%, and area under the receiver operating characteristic curve (AUC ROC) 0.770.
Although the NMC rule shows very attractive risk prediction performance, one must approach these results with caution due to two important limitations of this study. Th e fi rst is that the rule was derived from a singlecenter retrospective chart review study and it was created and validated in the same population. Th at was the same problem the Paphitou rule encountered, as performance in the original single-center study was quite predictive, but when we attempted to validate it in a multicenter data set, the rule lost a signifi cant amount of sensitivity and specifi city. Th e second limitation is more technical, and it has to do with attempting to evaluate PPV and NPV in case-control studies with an artifi cially created 'incidence' of disease. In the case-control study the incidence of IC would be 25%, which is 10 times higher than the incidence seen typically in patients who have an ICU length of stay ≥4 days.
Nevertheless, the NMC rule is a welcome addition to a set of clinical prediction rules that are currently in various stages of validation in prospective studies, such as the Candida score [8, 9] and the MSG rule [10] . One can envision a near future in which ICU patients are systematically screened for risk of IC while in the ICU, giving them access to antifungal prophylaxis or enhanced
